Olivier Bezencon

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Journal: Journal of medicinal chemistry

Published: August 12, 2025

Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia.

Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia.

Journal: Bioorganic & medicinal chemistry

Published: December 06, 2024

Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs.

Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs.

Journal: Bioorganic & medicinal chemistry

Published: July 01, 2024

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Journal: Journal of medicinal chemistry

Published: November 09, 2017

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Journal: Chimia

Published: October 27, 2017

Discovery and evaluation of Cav3.2-selective T-type calcium channel blockers.

Discovery and evaluation of Cav3.2-selective T-type calcium channel blockers.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2017

Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers.

Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2017

Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Journal: Journal of medicinal chemistry

Published: February 25, 2017

Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Journal: Journal of medicinal chemistry

Published: December 10, 2016

Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.

Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.

Journal: Journal of medicinal chemistry

Published: September 01, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026